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Introduction
Multiple myeloma (MM) is the second most common hematolog-
ical malignancy in the world (1). Despite recent progress in new 
therapeutic options, this disease remains incurable, with a median 
survival not exceeding 5 years in adults. MM is characterized by 
the proliferation of clonal, long-lived plasma cells (PCs) within the 
BM associated with bone destruction, serum monoclonal gammo-
pathy, and organ dysfunction (1). MM often evolves at a slow rate 
from an age-dependent premalignant stage called monoclonal 
gammopathy of undetermined significance (MGUS) (2). The driv-
ing forces that promote the evolution from MGUS to active MM 
have remained obscure until now. Although a number of oncogenic 
events are associated with MM evolution (2, 3), the pathogenesis 
of MM could reflect not only cell-intrinsic alterations, but also the 
impact of host immune reactions. Indeed, accumulating evidence 
over the past decades demonstrates that the immune system plays 
a pivotal role in the surveillance of cancer (4, 5). Both innate and 
adaptive immune cells can recognize and destroy malignant PCs 
(6–9), and progressive immune suppression has been involved in 
the progression of MM (10, 11). Additional proof of MM control by 
immune components derives from the clinical use of immunomod-
ulatory drugs (IMiDs) whose antimyeloma properties rely, at least 
partially, on the costimulation of T and NK cells (12–14).
The interaction between CD226 (DNAM-1) with its ligands 
CD155 (PVR, necl-5) and CD112 (nectin 2) has recently emerged 
as a critical mechanism of immune defence against a wide range 
of malignancies (15–18). CD226 was originally described as an 
adhesion coreceptor stimulating NK cell– and CD8+ T cell–medi-
ated cytotoxicity against tumor cells (19). It has now become clear 
that this receptor has broader implications than originally thought 
in controlling NK cell and T cell function (20, 21). CD226 has been 
implicated in immunological synapse formation (22), T cell pro-
liferation and differentiation (23), and cytokine secretion (21, 24). 
Interestingly, CD112 and CD155 are often present at the surface of 
malignant PCs in MM patients, and CD226 strongly contributes 
to NK cell–mediated killing of MM cells in vitro (8, 9). Moreover, 
therapeutic agents commonly used in the management of MM, 
such as melphalan and bortezomib (Btz), upregulate CD226 lig-
ands and sensitize MM cells to NK cell–mediated cytotoxicity (25, 
26). Altogether, this suggests that CD226 may play an important 
role in MM pathogenesis, and modulation of this pathway may 
have therapeutic implications.
Multiple myeloma (MM) is an age-dependent hematological malignancy. Evaluation of immune interactions that drive MM 
relies on in vitro experiments that do not reflect the complex cellular stroma involved in MM pathogenesis. Here we used 
Vk*MYC transgenic mice, which spontaneously develop MM, and demonstrated that the immune system plays a critical 
role in the control of MM progression and the response to treatment. We monitored Vk*MYC mice that had been crossed 
with Cd226 mutant mice over a period of 3 years and found that CD226 limits spontaneous MM development. The CD226-
dependent anti-myeloma immune response against transplanted Vk*MYC MM cells was mediated both by NK and CD8+  
T cells through perforin and IFN-γ pathways. Moreover, CD226 expression was required for optimal antimyeloma efficacy 
of cyclophosphamide (CTX) and bortezomib (Btz), which are both standardly used to manage MM in patients. Activation of 
costimulatory receptor CD137 with mAb (4-1BB) exerted strong antimyeloma activity, while inhibition of coinhibitory receptors 
PD-1 and CTLA-4 had no effect. Taken together, the results of this study provide in vivo evidence that CD226 is important 
for MM immunosurveillance and indicate that specific immune components should be targeted for optimal MM treatment 
efficacy. As progressive immunosuppression associates with MM development, strategies aimed to increase immune 
functions may have important therapeutic implications in MM.
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D and E). As shown previously (28), malignant PC expansion was 
mainly restricted to the BM in Vk*MYC mice (Figure 1, D and E, and 
Supplemental Figure 1). CD155 is a major ligand for CD226 and has 
been shown to play an important role in the immune recognition of 
cancer (20). Therefore, we analyzed CD155 expression on B220–
CD138+ PCs naturally arising from WT and Cd226–/– Vk*MYC mice. 
We found that CD155 was highly expressed on the cell surface of all 
the malignant PCs developing in transgenic Vk*MYC mice (Figure 
1E and Supplemental Figure 2). By contrast, this receptor was only 
expressed on a small fraction of PCs from normal mice (Supplemen-
tal Figure 1). Previous studies suggested that CD226 contributes to 
shape tumor immunogenicity, a process called cancer immunoedit-
ing (4), and that a decrease in CD155 expression on tumor cells may 
contribute to tumor immune escape (18). However, we observed 
that the level of CD155 expression on B220–CD138+ malignant PCs 
was similar between WT and Cd226–/– Vk*MYC mice, demonstrat-
ing that although CD226 impacts tumor development and survival, 
there is no detectable immunoediting of malignant PCs through 
CD226/CD155 interactions (Figure 1F).
CD226 interaction with CD155 on PCs limits MM development. 
We next investigated the mechanisms involved in the control of 
MM through the CD226 receptor. Given the timeframes required to 
modify immune components in the spontaneous Vk*MYC model, 
we decided to use a tractable transplantable model of Vk*MYC MM 
(Supplemental Figure 2). First, to confirm the role of CD226 receptor 
in the control of MM growth, WT and Cd226–/– mice were injected 
with 2 × 106 Vk12653 MM cells and were bled every 2 weeks to ana-
lyze M-spike levels. We observed a striking increase in serum para-
protein levels between Cd226–/– and WT mice 3 weeks after injec-
tion (Figure 2A). After 5 weeks, the number and the percentage of 
B220–CD138+ PCs recovered from the spleen and the BM were both 
significantly increased in Cd226–/– mice as compared to WT mice 
(Figure 2, B and C, and Supplemental Figure 3). Similar results were 
obtained with an independent MM cell line derived from Vk*MYC 
transgenic mice, Vk12598 (Figure 2D and Supplemental Figure 2). 
Finally, we found that mice injected with Vk12598 cells succumbed 
significantly faster to MM in the absence of CD226 (Figure 2E). 
Decreased survival of Cd226–/– mice compared to WT mice was also 
observed following the injection of low numbers of Vk12653 cells 
(Supplemental Figure 3). Given the high level of CD155 expression 
on Vk*MYC cells, we wanted to determine whether CD155 was 
involved in the CD226 control of Vk*MYC MM cells. To this end, we 
transplanted Vk*MYC cells into WT mice injected with anti-CD155, 
anti-CD226 or control Ig (cIg) as described in Methods. Both anti-
CD155 mAb– and anti-CD226 mAb–treated mice had higher γ-glob-
ulin levels 3 weeks after injection as compared to cIg-treated mice 
(Figure 2F). The percentages of B220–CD138+ PCs in the spleen and 
the BM were also significantly increased when CD155 or CD226 
receptors were blocked (Figure 2G). CD155 can be expressed on 
several immune cell types after activation, including DC, macro-
phages, and T lymphocytes. To determine whether endogenous or 
tumor-derived CD155 was important for the control of MM progres-
sion through CD226, we monitored MM growth in Cd155–/–, Cd155+/–, 
and Cd155+/+ littermates treated with cIg or anti-CD155. We did not 
observe any significant differences in MM growth between Cd155–/–, 
Cd155+/–, and Cd155+/+ mice (Figure 2H). By contrast, anti-CD155 
blockade increased tumor burden in Cd155–/– mice, suggesting that 
Most of our understanding of immune interactions with MM 
relies on in vitro experiments. Given the importance of BM stroma 
in the biology of MM, and the complex cellular and cytokine inter-
actions contributing to MM development, the previous results 
should be taken with some caution (27). Vk*MYC transgenic mice, 
which drive sporadic MYC oncogene expression in germinal center 
B cells, have recently emerged as the most relevant mouse model 
of MM currently available (28, 29). Vk*MYC mice spontaneously 
develop MGUS that progresses into indolent MM over 20–50 
weeks, and closely mirrors human MM pathological progression. 
This includes PC neoplasia restricted to the BM, bone destruction, 
and monoclonal gammopathy (28). Vk*MYC mice were shown to 
respond to most of the conventional antimyeloma drugs and thus 
represent a valuable preclinical tool to test new MM therapies in 
immune-competent hosts (30, 31).
In this study using this unique mouse model of MM, we 
demonstrate the importance of NK and CD8+ T cells in MM immu-
nosurveillance and response to treatment in vivo through CD226 
and CD155 interactions.
Results
CD226 limits spontaneous MM burden in Vk*MYC mice. To assess 
the role of CD226 in MM emergence and progression, we crossed 
Vk*MYC with Cd226–/– mice. The presence of monoclonal Ig 
(M-spike) and the level of γ-globulin in the serum were quantified in 
Cd226–/–, Cd226+/–, and Cd226+/+ Vk*MYC transgenic and nontrans-
genic littermates by serum protein electrophoresis (SPEP). Cd226+/+, 
Cd226–/–, and Cd226+/– Vk*MYC transgenic mice all developed 
detectable serum paraproteinemia (M-spike) between 200 and 400 
days of age (Supplemental Figure 1; supplemental material available 
online with this article; doi:10.1172/JCI77181DS1) that gradually 
increased overtime (Figure 1A). As previously described (28), some 
aged nontransgenic littermates also developed mild gammopathy 
irrespective of Cd226 genotype (Supplemental Figure 1). Inter-
estingly, although the incidence of M-spike was similar between 
groups of Vk*MYC transgenic mice, we observed that the levels of 
serum γ-globulin increased significantly faster in Cd226–/– Vk*MYC 
mice than in Cd226+/– Vk*MYC and Cd226+/+ Vk*MYC mice (Fig-
ure 1, A and B). In accordance with their higher serum paraprotein 
levels, Cd226–/– Vk*MYC mice had a significantly reduced overall 
survival, as compared to Cd226+/– and WT Vk*MYC littermates 
(Figure 1C and Supplemental Figure 1). By contrast, nontransgenic 
littermates survived longer than Vk*MYC transgenic mice, and they 
died of “old age” with similar kinetics regardless of the presence or 
absence of CD226 (Figure 1C and Supplemental Figure 1).
Our results suggested that CD226 does not drastically affect 
activation induced deaminase–dependent (AID-dependent) spon-
taneous MYC activation associated with MM emergence in vivo (28, 
29). By contrast, it demonstrated that CD226 significantly limited 
MM progression and improved survival. To confirm this hypothesis, 
we analyzed the level of PCs in the BM of a second cohort of Cd226–/– 
and Cd226+/+ Vk*MYC transgenic and nontransgenic littermates at 
an early stage of the disease. We found that Cd226–/– Vk*MYC mice 
had significantly higher percentages and numbers of BM B220–
CD138+ PCs compared with the WT counterparts (Figure 1, D and 
E). By contrast, the percentages and numbers of PCs in the BM of 
both Cd226–/– and WT nontransgenic mice were very low (Figure 1, 
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the spleen and the BM of NK cell– or CD8+ T cell–depleted mice 
were also significantly increased, as compared with Ig-treated 
mice (Figure 3A). Interestingly, mice that lacked both NK cells and 
CD8+ T cells had significantly higher γ-globulin levels and spleen 
weight than mice that lacked only one of these two lymphocyte 
subsets (Figure 3A and Supplemental Figure 4) suggesting that NK 
cells and CD8 T cells play additive roles in MM control in vivo.
The granule exocytosis pathway involving perforin and gran-
zymes, and the release of proinflammatory cytokines such as 
IFN-γ, are the two main mechanisms contributing to NK cell– and 
CD8+ T cell–tumor immunosurveillance (32, 33). Therefore, to gain 
more insight into the mechanism of CD226-dependent control 
of MM by NK cells and CD8+ T cells, we analyzed MM burden in 
tumor CD155 is more important than endogenous CD155 in con-
trolling MM progression. Altogether, these results demonstrate a 
key role for CD226 interaction with CD155 expressed by PCs in the 
control of MM development.
NK cells and CD8+ T cells exert antimyeloma activity through 
perforin and IFN-γ pathways. To characterize the immune cells 
involved in the CD226-dependent antimyeloma response in vivo, 
we first monitored MM burden in mice depleted of NK cells and/or 
CD8+ T cells using mAbs. Three weeks after injection of Vk12653 
cells, both NK cell–depleted mice (anti-asialoGM1 [anti-AsGM1]) 
and CD8+ T cell–depleted mice (anti-CD8β) had higher parapro-
tein levels than cIg-treated mice (Figure 3A and Supplemental 
Figure 4). The percentage of B220–CD138+ PCs recovered from 
Figure 1. CD226 limits spontaneous MM progression. (A–C) C57BL/6 Cd226+/+ (n = 55), Cd226–/+ (n = 27), and Cd226–/– (n = 25) Vk*MYC transgenic mice, 
along with Cd226+/+ (n = 12), Cd226–/+ (n = 15), and Cd226–/– (n = 9) nontransgenic littermate controls, were monitored for MM development (A and B) 
and survival (C). (A and B) Cd226–/– Vk*MYC mice have higher γ-globulin levels. (A) Graph showing the mean γ-globulin levels ± SEM in the serum of the 
indicated strains of mice over time. (B) Representative SPEP of Cd226+/+ and Cd226–/– Vk*MYC transgenic mice after 500 days. Arrows indicate M-spike. (C) 
Kaplan Meyer curves showing a significant decrease in the survival of Cd226–/– Vk*MYC mice as compared to WT and Cd226–/+ Vk*MYC littermates. (D–F) 
Cd226–/– Vk*MYC transgenic mice have an increased frequency of malignant PCs expressing CD155 in the BM. The percentage and the number of malignant 
PCs and their level of CD155 expression were analyzed by FACS in the BM of Cd226+/+ (n = 15) and Cd226–/– (n = 14) Vk*MYC transgenic mice and in Cd226+/+ 
(n = 6) and Cd226–/– (n = 10) nontransgenic littermate controls. (D and E) Graphs (D) and representative FACS plots (E) showing the mean frequency and 
number ± SEM of CD138+CD155+ malignant PCs in the BM of the indicated strains of mice at 450 days of age. (F) Graph showing similar level of CD155 
expression on B220–CD138+ BM PCs from Cd226–/– Vk*MYC and Cd226+/+ Vk*MYC mice. Each symbol represents 1 individual mouse. *P < 0.05, **P < 0.01, 
***P < 0.001; Mann-Whitney U test (A and D) Mantel-Cox test (C).
The Journal of Clinical Investigation R e s e a R c h  a R t i c l e
2 0 8 0 jci.org   Volume 125   Number 5   May 2015
M-spike levels were significantly higher in Ifng–/– mice (Figure 3B), 
suggesting that perforin and IFN-γ both participate in the antimy-
eloma immune response, but at slightly different times. Perforin 
and IFN-γ may also have slightly different roles depending on the 
location of the MM. Indeed, we found that the antimyeloma effects 
of perforin were restricted to the BM, where Pfp–/– mice contained 
mice deficient of perforin (Pfp–/–) and IFN-γ (Ifng–/–). Within 1 week 
after Vk12653 MM cell injection, we detected higher paraprotein 
levels in Pfp–/– mice than in Ifng–/– and WT mice (Figure 3B). After 
3 weeks, both Pfp–/– and Ifng–/– mice had higher paraprotein levels 
than WT mice (Figure 3B). Finally, while no significant differences 
were observed after 5 weeks between WT and Pfp–/– mice, the 
Figure 2. The interaction between CD226 and tumor CD155 is required for the immune-control of MM. (A–C) WT or Cd226–/– mice were challenged i.v. with  
2 × 106 Vk12653 cells. (A) Representative SPEP and graph showing the mean γ-globulin level ± SEM in the serum of the indicated strain of mice. Arrows indi-
cate M-spike. (B) Representative FACS plots showing the frequency of CD138+B220– PCs in the BM and the spleen 5 weeks after injection. (C) Graphs showing 
the mean number of PCs in the BM and the spleen. Representative experiment out of 4 involving groups of n = 10 mice. (D and E) WT or Cd226–/– mice were 
challenged i.v. with 4 × 105 Vk12598 MM cells. Graphs showing the percentage of malignant PCs was in the spleen (SPL) 3 weeks after injection (D) and the sur-
vival of mice over time (E). Representative experiment out of 2 involving groups of n = 10 mice. (F and G) WT mice were injected with anti-CD226, anti-CD155, 
or control IgG (cIg) before Vk12653 MM cell injection. (F) Mean serum γ-globulin level ± SEM 3 weeks after MM injection. (G) Graphs showing the percentages 
of B220–CD138+ PCs in the SPL and BM. Representative experiment out of 2 involving groups of n = 10 mice. (H) Cd155–/–, Cd155+/–, and WT littermates were 
injected with anti-CD155 or control IgG before Vk*MYC challenge. Graph showing the number of B220–CD138+ PCs in the SPL. Data are from 2 pooled exper-
iments involving groups of n = 7–14 mice. Each symbol represents 1 individual mouse. *P < 0.05, **P < 0.01, ***P < 0.001. Kruskall-Wallis test was used for 
multiple comparisons, Mann-Whitney U test was used for single comparison between groups, and Mantel-Cox test was used for survival analysis.
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analyzed by flow cytometry. We observed a significant decrease in 
CD8+ T cell and NK cell percentages in the blood of Vk*MYC mice 
as compared to nontransgenic mice (Figure 4, A and B). A similar 
decrease in NK cells and CD8+ T cells was observed in the BM of 
mice injected with Vk12653 MM cells, as compared to noninjected 
mice (Figure 4C). Finally, we found an inverse correlation between 
the number of BM PCs and the percentage of NK cells and CD8+ T 
cells, demonstrating that MM burden is associated with a decrease 
in the percentage of NK and CD8+ T cells in the BM (Figure 4D). 
We next analyzed CD226 expression on CD8+ T cells and NK cells 
and observed that, in both spontaneous and transplanted Vk*MYC 
models, a decrease in cell surface expression of CD226 on CD8+ T 
cells and NK cells was associated with MM progression (Figure 4, 
E and F). In addition, the number of BM PCs was inversely cor-
related to the expression of CD226 on NK and CD8+ T cells (Figure 
4G). Altogether, our results show that progressive immune defects 
are associated with MM development.
a higher fraction of B220–CD138+ PCs than WT mice (Figure 3C). 
By contrast, Ifng–/– mice had higher spleen weight and contained 
significantly higher percentages and numbers of MM cells in the 
spleen than WT and Pfp–/– mice (Figure 3D and Supplemental Fig-
ure 4). Finally, we found that IFN-γ–deficient mice injected with 
Vk12653 or Vk12598 MM cells had a significantly shorter survival 
than WT or Pfp–/– mice (Figure 3, E and F). Therefore, although per-
forin and IFN-γ are both involved in the immune control of MM, 
the impact of IFN-γ deficiency was more pronounced, reinforcing 
the importance of this pathway in disease control by immune cells.
Progressive immune defects are associated with MM progression 
in vivo. MM has been associated with a progressive dysfunction of 
NK cells and CD8+ T cells (10, 11). To better understand the impact 
of myeloma progression on host immune responses, we first ana-
lyzed immune populations during MM development in vivo. 
Vk*MYC mice bearing spontaneous MM and nontransgenic con-
trol mice were bled at 600 and 700 days, and peripheral blood was 
Figure 3. Critical role for NK and CD8+ T 
cells in the control MM through perfo-
rin and interferon-γ pathways. (A) NK 
cells and CD8+ T cells limit Vk*MYC MM 
burden in vivo. WT mice were injected with 
control IgG, anti-AsGM1 and/or anti-CD8β 
to deplete NK cells and/or CD8+ T cells, 
and were challenged with Vk12653 cells. 
The γ-globulin levels in the serum of the 
indicated groups of mice 3 weeks after 
injection, and the percentages and numbers 
of CD138+B220– PCs in the BM and in the 
spleen (SPL) of the indicated groups of mice 
are shown. Representative experiment out 
of 2 involving groups of n = 10 mice. (B–D) 
WT, Pfp–/–, and Ifng–/– mice were injected i.v. 
with 2 × 106 Vk12653 cells. (B) MM burden 
was evaluated by SPEP 1, 3, and 5 weeks 
after injection. The γ-globulin levels in the 
serum of the indicated groups of mice are 
shown. (C and D) the percentages and num-
bers of CD138+B220– PCs in the BM (C) and 
in the SPL (D) of the indicated groups of 
mice are shown. Representative experiment 
out of 2 involving groups of n = 10 mice. 
(E and F) WT, Pfp–/–, and Ifng–/– mice were 
injected i.v. with 5 × 105 Vk12653 cells (E) or 
4 × 105 Vk12598 cells (F), and the survival of 
mice was analyzed after injection. Groups 
of n = 10 mice are shown. Each symbol rep-
resents 1 individual mouse. *P < 0.05,  
**P < 0.01, ***P < 0.001; Mann-Whitney U 
test (A–D) and Mantel-Cox test (E and F).
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Optimal antimyeloma therapy requires CD226. It is now well 
established that the in vivo antitumor efficacy of chemotherapy 
can rely on the activation of the immune system (34, 35). However, 
in the absence of a mouse myeloma model, the role of immune 
components in the clinical efficacy of antimyeloma drugs such as 
Btz and cyclophosphamide (CTX) remained to be determined. 
To address this question, cohorts of WT and Cd226–/– mice were 
injected with Vk12653 MM cells. After 3 weeks, when mice started 
to develop measurable M-spike, mice were injected either with cIg 
or anti-CD226 mAbs and were subsequently treated with PBS, Btz 
(i.p.; 0.5 mg/kg), or CTX (i.p.; 50 mg/kg) twice a week (Supplemen-
tal Figure 5). Evolution of tumor burden was assessed every week by 
Figure 4. Progressive immunosuppression is associated with myeloma progression in vivo. (A and B) Representative FACS plots (A) and graphs (B) show-
ing the percentages of TCRβ+CD8+ cells and NK1.1+TCRβ– NK cells in the peripheral blood of Cd226+/+ Vk*MYC mice (n = 20) and nontransgenic control mice  
(n = 7) at 600 and 700 days. (C) Graphs showing the numbers of TCRβ+CD8+ cells and NK1.1+TCRβ– NK cells in the BM of naive mice or mice injected with 
Vk12653 MM cells for 5 weeks. Representative experiment out of 2 involving groups of n = 5–10 mice. (D) Graphs showing the correlation between the 
percentage of NK and CD8+ T cells and the number of BM PCs in the BM of mice injected with Vk12653 cells for 5 weeks (n = 61). Pearson r coefficient and 
associated P values are shown. (E) Graphs showing the mean fluorescence intensity (MFI) of CD226 on CD8+ T cells and NK cells as in A. (F) Representative 
histogram plots and graphs showing the MFI of CD226 staining on NK cells and CD8+ T cells as in C. Isotype control staining (gray line), and CD226 staining 
on naive mice (black line) and MM-bearing mice (dotted line) are shown. (G) Graph showing the correlation between the expression of CD226 on NK cells and 
CD8+ T cells and the number of BM PCs in the BM of mice injected with Vk12653 cells for 5 weeks (n = 20). Pearson r coefficient and associated P values are 
shown. Each symbol represents 1 individual mouse. *P < 0.05, **P < 0.01, ***P < 0.001; paired Student’s t test (B and E) and Mann-Whitney U test (C and F).
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SPEP (Figure 5, A and B). CTX was very effective in limiting tumor 
progression. All groups of mice (WT mice plus Ig, WT mice plus 
anti-CD226, or Cd226–/– mice) had almost undetectable M-spike 
after 3 weeks of treatment, while vehicle-treated mice all developed 
severe paraproteinemia (Figure 5, A and B). Vk12653 cells have been 
selected for increased resistance to Btz treatment (30, 31). Indeed, 
we found that Vk12653 cells were less sensitive to Btz than CTX, but 
we still observed a significant reduction in γ-globulin levels in WT 
mice treated with Btz (Figure 5, A and B). Surprisingly, in Cd226–/– 
mice or WT mice injected with anti-CD226 mAbs, Btz treatment 
failed to limit M-spike progression, suggesting that the absence of 
CD226 may affect the efficacy of Btz treatment (Figure 5, A and B).
The spleen and BM from different groups of mice were then col-
lected after 3 weeks of treatment and analyzed by FACS for MM cell 
infiltration. All groups of vehicle-treated mice reached end point 
disease and had massive tumor infiltration in the BM and the spleen 
(Figure 5, C and D, and Supplemental Figure 5). WT mice treated 
with CTX had almost undetectable CD138+CD155+ malignant PCs 
in the BM and the spleen. WT mice injected with anti-CD226 mAbs 
or Cd226–/– mice also had a drastic decrease in the percentage and 
number of tumor cells in the BM and the spleen after CTX treat-
ment, but in contrast to WT mice, a bigger residual population of 
CD138+CD155+ malignant PCs was still detectable in the absence of 
CD226 in both the BM and the spleen (Figure 5, C and D, and Sup-
plemental Figure 5). As a consequence, CTX-treated Cd226–/– mice 
quickly succumbed to MM after the end of the treatment, unlike 
CTX-treated WT mice that survived significantly longer than vehi-
cle-treated mice (Supplemental Figure 5). Btz therapy also induced 
a significant decrease in tumor burden in WT mice, although it was 
less effective in limiting MM progression than CTX (Figure 5, C 
and D, and Supplemental Figure 5). Surprisingly, the percentages 
and the numbers of CD138+CD155+ tumors in the BM and spleen 
of Cd226–/– mice or anti-CD226–injected WT mice were not sig-
nificantly reduced after Btz treatment, suggesting that the in vivo 
efficacy of this agent requires an intact CD226 pathway (Figure 5, 
C and D, and Supplemental Figure 5). To confirm these findings, 
we performed similar experiments using another Vk*MYC cell line. 
While Btz treatment significantly increased the survival of WT mice 
injected with Vk12598 MM cells, we observed that its therapeutic 
effect was compromised in Cd226–/– mice (Figure 5E). Altogether, 
these results demonstrate that the immune system affects the in 
vivo efficacy of the antimyeloma drugs CTX and Btz.
Therapeutic efficacy of anti-CD137 immunotherapy against mye-
loma. Harnessing the immune system to fight tumors has recently 
proven to be a successful strategy to treat cancer patients (36). mAbs 
blocking lymphocyte inhibitory receptors programmed death 1 (PD-1; 
Figure 5. Optimal antimyeloma therapy requires CD226. (A–E) The therapeutic efficacy of Btz and CTX is altered in the absence of CD226. (A–D) WT 
and Cd226–/– mice were injected i.v. with 2 × 106 Vk12653 MM cells. After 3 weeks (indicated by arrows), mice were injected either with IgG or anti-CD226 
mAbs and were subsequently treated with vehicle (PBS), Btz (i.p.; 0.5 mg/kg), or CTX (i.p.; 50 mg/kg) twice a week. (A and B) Serum paraproteinemia was 
analyzed every week by SPEP. Graphs showing the mean γ-globulin percentages ± SEM in the indicated groups of mice over time (A) and after 3 weeks of 
treatment (B). (C and D) Representative FACS plot showing the percentages (C) and graphs showing the numbers (D) of malignant CD138+CD155+ PCs in the 
BM of the indicated groups of mice at the end of the treatment. Data are pooled from 2 independent experiments involving 9 groups of n = 9–12 mice. Each 
symbol represents 1 individual mouse. (E) WT and Cd226–/– mice were injected i.v. with 4 × 105 Vk12598 MM cells. After 1 week, mice were treated with PBS 
or Btz (i.p.; 0.5 mg/kg) twice a week for 4 weeks, and the survival of the indicated groups of mice was monitored. Experiment involving groups of n = 10 
mice. *P < 0.05, **P < 0.01, ***P < 0.001; Mann-Whitney U test (A, B, and D) and Mantel-Cox test (E).
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in the BM and the spleen after 3 weeks of treatment revealed that 
anti-CD137 mAbs induced a drastic reduction in myeloma burden in 
most of the mice treated (Figure 6, C–E). Long-term survival analy-
ses revealed that anti-CD137 mAb–treated mice have a significantly 
longer survival than PBS-treated mice (Figure 6F). These findings 
were confirmed in another in vivo model of MM, since we observed 
that anti-CD137 treatment also significantly increased the survival 
of WT mice injected with Vk12598 MM cells (Figure 6G). Surpris-
ingly, anti-CD137 treatment also led to a significant reduction of MM 
development in Cd226–/– mice or in mice treated with anti-CD226 
mAbs (Figure 6H and Supplemental Figure 6), suggesting that the 
presence of functional CD226 is dispensable for the antimyeloma 
response to anti-CD137 mAb immunotherapy.
Anti-CD137 immunotherapy against myeloma requires NK and 
CD8+ T cells. To gain more insight into the mechanism involved in 
the antimyeloma effect of anti-CD137 mAb, we performed a phe-
notypic analysis of immune cells infiltrating the BM of Ig-treated 
CD279) and CTLA-4 (cytotoxic T lymphocyte antigen 4; CD152) 
or stimulating coreceptor CD137 (4-1BB, TNFRSF9) are among the 
most promising therapies currently in the clinic (37–39). However, 
due to the lack of reliable MM models, the efficacy of such therapies 
remain unclear in MM. To answer such questions, WT mice were 
prophylactically injected with cIg, anti-CD137, anti–PD-1, or anti–
CTLA-4, and subsequently challenged with Vk*MYC MM cells. We 
could not detect any significant differences in tumor burden between 
control mice treated with anti–PD-1, anti–CTLA-4, and cIg (Figure 6, 
A and B, and Supplemental Figure 6). By contrast, a striking reduc-
tion in the number and percentages of malignant PCs were observed 
in mice treated with anti-CD137 mAbs (Figure 6, A and B, and Sup-
plemental Figure 6). We next analyzed the antimyeloma effect of 
anti-CD137 mAbs as a therapeutic agent. Cohorts of WT mice were 
injected with Vk12653 MM cells. After 3 weeks, when mice started 
to develop measurable M-spike, mice were injected either with cIg 
or anti-CD137 mAbs. Analysis of serum Ig levels and PC content 
Figure 6. Therapeutic efficacy of anti-CD137 immunotherapy against myeloma. (A and B) WT mice were injected with cIg, anti-CD137, anti–PD-1, or 
anti–CTLA-4 and subsequently challenged with 2 × 106 Vk12653 MM cells. Representative FACS plot showing the percentages (A) and graphs showing the 
numbers (B) of CD138+CD155+ PCs in the BM at the end of the treatment. Data are representative of 2 independent experiments involving groups of n = 10 
mice. (C–F) WT mice were injected i.v. with 2 × 106 Vk12653 MM cells. After 3 weeks, mice were injected either with IgG or anti-CD137 mAbs. Representative 
FACS plot and graph showing the percentages (C), the mean γ-globulin percentages (D), the mean numbers ± SEM of malignant CD138+CD155+ PCs in the 
BM (E) and the survival (F) of the indicated groups of mice. Each symbol represents 1 individual mouse. (G) WT mice were injected i.v. with 4 × 105 Vk12598 
MM cells. After 1 week, mice were treated with IgG or anti-CD137 mAb twice a week for 4 weeks, and their survival was monitored. Experiment involving 
groups of n = 10 mice. (H) WT and Cd226–/– mice were injected i.v. with 2 × 106 Vk12653 MM cells. After 3 weeks, mice were injected either with IgG or anti-
CD226 mAb and were subsequently treated with cIg or anti-CD137. Graphs show the percentages and the mean numbers ± SEM of malignant CD138+CD155+ 
PCs in the BM at the end of the treatment. Data are pooled from 2 independent experiments. **P < 0.01, ***P < 0.001, ****P < 0.0001; Mann-Whitney U 
test (B, D, E, and H) and Mantel-Cox test (F and G).
The Journal of Clinical Investigation   R e s e a R c h  a R t i c l e
2 0 8 5jci.org   Volume 125   Number 5   May 2015
CD137 therapy, while their percentage among BM CD4+ T cells was 
significantly decreased (Figure 7, A–C, and Supplemental Figure 7). 
As a consequence, anti-CD137 therapy induced a strong increase 
in the ratio between CD8+ T cells and Tregs. Recent evidence sug-
gests that mAb-based immunotherapy can act through the Fc- 
or anti-CD137 mAb–treated mice. We observed a robust increase 
in the number and the percentages of CD8+ T cells infiltrating the 
BM after 3 weeks of anti-CD137 mAb treatment, as compared to the 
cIg-treated mice (Figure 7, A–C, and Supplemental Figure 7). By con-
trast, the number of BM FOXP3+ Tregs remained stable after anti-
Figure 7. Mechanism of anti-CD137 immunotherapy against myeloma. (A–H) The indicated groups of mice were injected i.v. with 2 × 106 Vk12653 MM 
cells. After 2–3 weeks, mice with established MM were injected either with IgG, anti-CD137, or anti–PD-1 mAbs. (A–C) Representative FACS plot (A) and 
graphs showing the percentages (B) and the number (C) of the indicated populations of immune cells after 3 weeks of treatment with cIg or anti-CD137. 
Data are pooled from 2 independent experiments. (D and E) Graphs showing the percentages and the number of malignant PCs (D) or CD8+ T cells (E) in the 
BM of WT, Fcgr3a–/–, or Fcer1g–/– mice treated with IgG or anti-CD137 mAb. (F and G) Representative FACS plot (F) and graphs showing the percentages (G) 
of NK cells or CD8+ T cells expressing CD69 activation marker 6 days after the beginning of the indicated treatment. Data are pooled from 2 independent 
experiments. (H) Mice were injected with control IgG, anti-CD8β, anti-AsGM1, or anti-CD4 to deplete CD8+, NK, or CD4+ cells before anti-CD137 therapy. The 
percentages and the number of CD138+B220– PCs were analyzed by flow cytometry in the BM of the indicated groups of mice at the end of the treatment. 
Representative experiment out of 2 involving groups of n = 10 mice. *P < 0.05, **P < 0.01, ***P < 0.001; Mann-Whitney U test.
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Oncogene activation is a powerful inducer of cellular stress 
that not only activates apoptosis or senescence cellular programs 
(43), but also stimulates immune recognition through the upregula-
tion of NKG2D and CD226 ligands (25, 44–46). It has recently been 
demonstrated in the EμMYC transgenic mouse model that replica-
tion stress induced by MYC overexpression is a strong inducer of 
CD155 expression (47). Our study demonstrates that malignant 
PCs developing in Vk*MYC mice all displayed a high expression of 
CD155, as compared to normal PCs. Although no formal proof has 
been established, this suggests that genomic stress associated with 
MYC overexpression may be at the origin of CD155 expression on 
transformed PCs in Vk*MYC mice. Similar mechanisms may occur 
in MM patients, since MYC and MYC target genes — as well as 
CD155 — are often overexpressed in malignant PCs isolated from 
patients (8, 28). Our study suggests that the expression of CD155 
may represent a strong determinant of MM immunogenicity, and 
an extensive understanding of the clinical impact of this ligand 
expression in MM patients is now required. CD226 was also shown 
to interact with CD112 (48, 49), but the relevance of CD112/CD226 
interactions in mice remains unclear (50). Although, CD112 expres-
sion was usually low or absent on Vk*MYC MM cells, this ligand 
was found to be expressed on human MM cells and could also play 
a role in the pathogenesis of this disease (8).
Recent studies indicate that the efficacy of several chemother-
apies in vivo relies on the immune system (34). Although most 
antimyeloma agents are thought to act primarily through direct 
cytotoxic effects, additional effects on the immune system may 
contribute to their efficacy in vivo. We observed that the absence of 
CD226 or neutralization of this receptor affected the antimyeloma 
activity of CTX and Btz, providing strong evidence that immune 
components and CD226 may represent strong determinants of 
antimyeloma treatment efficacy. Low-dose CTX has been shown 
to deplete Tregs and restore T and NK cell functions (51–54). The 
depletion or neutralization of Tregs and the reactivation of NK and 
CD8+ effector lymphocytes upon CTX treatment may account for 
the immune-dependent action of CTX in our experiment.
Despite being one of the most active drugs used in the manage-
ment of MM, malignant PCs often acquire resistance to Btz, lead-
ing to patient relapse (29). Therefore, to mimic more closely what 
may happen in human patients, we chose to identify the role of 
immune components using Btz-resistant tumor cells, Vk12653 and 
Vk12598 (30, 31). Although Vk12653 and Vk12598 cells were less 
sensitive to Btz than CTX, the progression of MM was still signifi-
cantly affected by Btz treatment in immune-competent mice. How-
ever, the antimyeloma efficacy of Btz was completely lost in the 
absence of CD226, suggesting that the in vivo efficacy of this drug 
mainly relies on immunity. Such results suggest that immunother-
apeutic approaches may greatly enhance the efficacy of this drug in 
MM, and future experiments will have to determine the underlying 
mechanisms of the CD226-dependent effects of Btz. Part of the 
effect of this drug might be mediated through NK cell activation, 
since Btz was shown to augment the efficacy of adoptively trans-
ferred NK cells in both murine tumor models and cancer patients 
(55, 56). Indeed, proteasome inhibitors alter MHC class I (MHC-I) 
peptide processing machinery, and MM cells treated with Btz have 
reduced cell surface expression of MHC-I and are more susceptible 
to NK cell–mediated killing (57). Btz has also been shown to stimu-
dependent depletion of tumor-associated Tregs (40). We found that 
a significant fraction of Tregs express CD137 (Supplemental Figure 
7), suggesting that a depletion of Tregs by anti-CD137 mAb may be 
involved in its therapeutic effects. However, Fc receptors were not 
involved in the antimyeloma effects of anti-CD137 mAbs (of the 
IgG2a isotype) since CD8+ T cell expansion, as well as BM MM cell 
burden, was similar in WT mice and mice lacking the Fc receptor 
common γ-chain (Fcer1g–/–) or the low affinity receptor for IgG2a/
IgG1/IgG2b (Fcgr3a–/–) (Figure 7, D and E). These results suggested 
that anti-CD137 mAbs may directly act on effector cells. Therefore, 
we analyzed NK and CD8+ T cell activation early after the beginning 
of the treatment and found that the CD69 activation marker was 
increased on BM NK cells and CD8+ T cells 6 days after CD137 mAb 
injection (Figure 7, F and G). By contrast, neither NK cells nor CD8+ 
T cells showed signs of activation after anti–PD-1 therapy, and the 
CD8+ cell/Treg ratio remained unchanged, which we have hypoth-
esized to explain the poor therapeutic responses obtained with this 
treatment in our model (Figure 7, F and G, and Supplemental Figure 
7D). We then treated MM-bearing mice with depleting mAbs against 
NK cells (anti-AsGM1), CD8+ T cells (anti-CD8β), or CD4+ T cells 
(anti-CD4) before anti-CD137 mAb treatment. We found that the 
anti-CD137 therapy was abrogated in the absence of CD8+ T cells 
or NK cells (Figure 7H). Conversely, we found that the depletion of 
CD4+ T cells did not alter the therapeutic effect of anti-CD137 mAbs. 
Altogether, these results point toward a critical role of NK cells and 
CD8+ T cells in anti-CD137–mediated antimyeloma activity.
Discussion
Until now, the lack of reliable mouse models has limited the under-
standing of immune interactions with MM in vivo. In this study — 
using the most clinically relevant mouse model of MM, Vk*MYC 
transgenic mice — we demonstrated that the immune system lim-
its spontaneous MM burden in vivo. We provided strong evidence 
that immune control of MM is mediated by NK cells and CD8+ T 
cells through CD226 interaction, with CD155 expressed on the cell 
surface of transformed PCs. Moreover, our results demonstrated 
that standard drugs used in the management of MM, CTX, and Btz 
also required CD226 for optimal antimyeloma efficacy in vivo. This 
seminal work suggests that CD226 may play an important role in 
MM pathogenesis. The translation of such findings in human MM 
patients and a better comprehension of immune receptor ligands 
that control the efficacy of antimyeloma therapy may have strong 
clinical applications.
Although a number of oncogenic events are associated with 
myeloma evolution, the driving forces that promote the evolution 
from MGUS to smoldering and active myeloma have remained 
obscure (2, 41). Primary oncogenic events such as IgH translo-
cations and hyperdiploidy have been associated with cell cycle 
deregulation, PC survival, and MGUS, while secondary IgH 
translocations, RAS mutations, and overexpression of MYC and 
MYC target genes have been associated with progression to active 
myeloma (2, 42). Our study suggests that host immune reaction 
may represent another key factor involved in the progression of 
MM. Management of MGUS and smoldering MM mainly involves 
a “watch and wait” strategy. Our results suggest that immune 
monitoring and immunotherapy may greatly impact the outcome 
for patients with a high risk of developing MM.
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ated with MM disease development. Analysis of BM and spleen lym-
phocyte populations after immunotherapy revealed that anti-CD137 
decreased Treg percentages and simultaneously increased CD8+ T 
cells, leading to a dramatic increase in the CD8 T cell/Treg ratio. 
Although such findings are reminiscent of the effect of anti–CTLA-4 
mAbs in solid tumors (40), unlike anti–CTLA-4, anti-CD137 effects 
were not mediated through an Fc-dependent depletion of Tregs. 
Consistent with a previous study (72), we found that anti-CD137 
therapy required the presence of both CD8+ T cells or NK cells, while 
CD4+ T cells were dispensable. Indeed, NK cells and CD8+ T cells 
were activated early after the beginning of anti-CD137 therapy, and 
their depletion abrogated the therapeutic effect of anti-CD137. MM 
growth relies on a complex network of cytokines and cellular interac-
tions (27). Future experiments will have to determine whether ther-
apy-induced changes in the BM microenvironment may alter this 
network and, by this mechanism, limit MM development. It would 
now be interesting to analyze the benefit of combining such treat-
ments with classical MM chemotherapy, such as Btz.
Methods
Mice. All mice used in this study were on a C57BL/6 genetic back-
ground. C57BL/6 WT mice were purchased from the Walter and Eliza 
Hall Institute for Medical Research or ARC Animal Resource Centre. 
Vk*MYC (Tg[Tgkv3-5-MYC]#Plbe) (28), Cd226–/– (16), and Pfp–/–, Ifng–/–, 
and Rag2–/– Il2rg–/– mice have already been described (73). Cd155–/– 
mice were provided by Yoshimi Takai (Kobe University, Kobe, Japan). 
Fcer1g–/– and Fcgr3a–/– mice were provided by Eva Orlowski (Burnet 
Institute, Melbourne, Australia). All mice were bred and maintained at 
either the Peter MacCallum Cancer Centre or QIMR Berghofer Medi-
cal Research Institute and were used between the ages of 6–14 weeks.
Vk*MYC aging experiments. Vk*MYC transgenic mice were 
crossed with Cd226–/– mice. Cd226+/+ (n = 55), Cd226–/+ (n = 27), and 
Cd226–/– (n = 25) Vk*MYC transgenic littermate controls, as well as 
Cd226+/+ (n = 12), Cd226–/+ (n = 15), and Cd226–/– (n = 9) nontrans-
genic littermate controls, were monitored for MM development and 
survival during a period of 3 years. The presence of monoclonal Ig 
(M-spike) and the level of γ-globulin in the serum were quantified 
by SPEP (HYDRASYS, Sebia Hydragel) every 2 months. The content 
of malignant PCs in the BM was determined in the different groups 
of mice postmortem (Supplemental Figure 1). A second cohort 
of Cd226+/+ (n = 15), Cd226–/– (n = 14) Vk*MYC transgenic mice, 
Cd226+/+ (n = 6), and Cd226–/– (n = 10) nontransgenic littermate con-
trols was culled at 450 days of age to analyze by flow cytometry the 
percentage of B220–CD138+ PCs in the BM and the spleen.
Vk*MYC transplantable model. Transplantable Vk*MYC MM cells 
Vk12653 and Vk12598 were generated as described previously (30). 
To remove any potential contaminant cells that may derive from the 
original host, we performed 2 successive transplants by i.v. injection of 
2 × 106 Vk12653 cells or 4 × 105 Vk12598 cells into Rag2–/– Il2rg–/– mice. 
After the second transplant, all Rag2–/– Il2rg–/– mice developed robust 
M-spikes 5 weeks after injection. Spleen cells from Rag2–/– Il2rg–/– mice 
containing at least 50% of malignant PCs were frozen and subse-
quently used as a reliable source of transplantable Vk*MYC cells for 
all our experiments (Supplemental Figure 2). The presence of mono-
clonal Ig in the serum was determined every 1, 3, and 5 weeks after 
MM cells injection by SPEP. The percentage and the number of B220–
CD138+ PCs was analyzed in the BM and the spleen by flow cytome-
late the expression of CD155 and NKG2D ligands at the cell surface 
of MM cells (26). CD155 expression is already high on Vk*MYC 
MM cells, but we cannot rule out that an increase in CD155 expres-
sion on accessory cells may contribute to the CD226-dependent 
MM reduction in Btz-treated mice. Alternatively, Btz treatment 
may also trigger immunogenic cell death of MM cells (34) and 
stimulate the presentation of tumor antigens to cytotoxic T cells. 
For example, previous study demonstrated that Btz increases the 
uptake of dying human myeloma cells by dendritic cells (58).
The inclusion of drugs such as IMiDs and Btz has resulted in a 
significant prolongation of survival of MM patients. However, MM 
is still an incurable disease with a median survival not exceed-
ing 5 years in adults (1). Immune stimulatory mAbs have recently 
emerged as a promising strategy and are currently tested in several 
malignancies, with the hope of further improving patients’ survival 
(59). Recent clinical trials have demonstrated a significant therapeu-
tic impact of PD-1 inhibition on a variety of solid tumors (37, 60). The 
broad expression of PD-1/PD-ligand 1 (PD-L1) in the microenviron-
ment of myeloma suggest this pathway may play an important role in 
the immune evasion by MM cells (61). Several studies demonstrated 
that PD-1 or PD-L1 blockade increases immune cell reactivity 
against malignant PCs (62–64). In our model, we could not observe 
any therapeutic or notable immune stimulatory effect of anti–PD-1 
treatment. However, we do not exclude that such a treatment 
administered with a different schedule or in combination with other 
immune stimulatory or chemotherapeutic agents may have potent 
antitumor activity. Indeed, we found that PD-1 expression is very 
low on spleen or BM effector cells in the early phase of MM develop-
ment, possibly explaining the low therapeutic activity of this drug in 
our model. However, we found that PD-1 was highly upregulated on 
CD8+ T cells and NK cells following anti-CD137 therapy, suggesting 
that anti–PD-1 mAbs may combine with anti-CD137 therapy.
Anti-CD137 is one of the most interesting immunostimulatory 
mAbs tested for cancer therapy (65–69). Currently, BMS-663513, a 
humanized anti-CD137 antibody, is in clinical trials in patients with 
solid tumors, including melanoma, renal carcinoma, ovarian cancer, 
and B cell malignancies (70). Our present results demonstrate that 
anti-CD137 exerts strong antimyeloma effects, providing a strong 
rationale for testing this agent in MM. It would now be interesting to 
analyze the benefit of combining such treatments with classical MM 
chemotherapy, such as Btz. Although CD226 had a strong impact in 
the control of MM burden in our model, the antimyeloma effects pro-
vided by anti-CD137 mAb therapy appeared independent of CD226. 
CD137-mediated signals were shown to increase DC maturation, to 
reverse CD8 T cell anergy, and to render effector T cells refractory to 
Treg-mediated suppression (66). Anti-CD137 mAb–mediated T cell 
activation may therefore bypass the requirement for CD226 costim-
ulatory signals. Indeed, besides its well-known role in cytotoxic-
ity, CD226 has also been shown to play an important role in T cell 
activation mediated by antigen-presenting cells (16, 22), and more 
recently, decreased CD226/CD155 interactions were shown to be an 
important feature of exhausted CD8+ T cells within human tumors 
(71). With the progression of MM, CD226 is often downregulated on 
effector cells (8), and therefore finding an immunotherapeutic agent 
that allows the targeting of malignant PCs independently of the 
CD226 pathway is a valuable discovery. Our study suggests that anti-
CD137 therapy may bypass the potential immune exhaustion associ-
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Cytometer (BD Biosciences). Analysis was performed with Flowjo 
software (Tree Star Inc.).
Statistics. Statistical analysis was achieved using GraphPad Prism 
6 software. A Kruskall-Wallis test was used for multiple comparisons 
between groups. When significant differences were found, a 2-tailed 
nonparametric Mann-Whitney test or unpaired t tests were then used 
for single comparisons between groups. Comparisons between paired 
samples were analyzed with 2-tailed paired t tests. A Mantel-Cox test 
was used for survival analysis. Correlation analyses between variables 
were performed using Pearson rank correlation test. A P value less than 
0.05 was considered significant (*P < 0.05, **P < 0.01, ***P < 0.001).
Study approval. All experiments were approved by Peter MacCal-
lum Cancer Centre and QIMR Berghofer Medical Research Institute 
animal ethics committees.
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try at the end of each experiment. Alternatively, the survival of mice 
injected with Vk12653 or Vk12598 was monitored over time.
Antimyeloma therapy. For prophylactic treatment, WT or Cd226–/– 
mice were injected with cIg, anti-CD137 (200 μg, 3H3; BioxCell), anti–
PD-1 (200 μg, RMP1-14; BioxCell), or anti-CTLA-4 (200 μg, UC10-
4F10; BioxCell) i.p. on days –1 and 0, and every week after MM cell injec-
tion. For a therapy experiment, WT and Cd226–/– mice were injected i.v. 
with 2 × 106 Vk12653 cells. After 3 weeks, when mice started to develop 
detectable M-spike, mice were randomly assigned into groups that 
received vehicle (PBS), CTX (i.p. 50 mg/kg, twice a week), Btz (i.p. 0.5 
mg/kg, twice a week), anti-CD137 (100 μg, twice a week, 3H3; Biox-
Cell), or anti–PD-1 (100 μg, twice a week, RMP1-14; BioxCell). Alter-
natively, mice injected i.v. with 4 × 105 Vk12598 MM cells were treated 
with the indicated antimyeloma drugs 1 week after MM cell injection.
Antibody treatments. In vivo antibody depletion and receptor 
blockade were performed using the following antibodies: control IgG 
(100 μg, HRPN; BioxCell), anti-CD4 (100 μg, GK1.5; BioxCell), anti-
CD8β (100 μg, 53.5.8; BioxCell), anti-AsGM1 (100 μg; Wako), anti-
CD226 (200 μg, 480.1), and anti-CD155 (200 μg, 4.24.3). All antibody 
injections were given i.p. on days –1 and 0, and every week after MM 
injection. Alternatively, antibody injections were given on days –1 and 
0, and every week after the beginning of the antimyeloma therapy.
Flow cytometry. Single-cell suspensions were stained with the fol-
lowing conjugated mAbs: anti–mouse CD3ε (145-2C11), TCRβ (H57-
597), CD4 (RM4-5), FOXP3 (FJK-16s), CD8α (53-6.7), NK1.1 (PK136), 
CD69 (H1.2F3), CD226 (480.1), CD112 (829038), CD155 (4.24.3), 
B220 (RA3-6B2), CTLA-4 (UC10-4B9), H-2Db (28-14-8), H2-Kb 
(AF6-88-5), Rae-1 (clone 186107), PD-1(RMP1-30), PD-L1 (10F.9G2), 
PD-L2 (clone 122), CD137 (17B5), CD137L (TKS-1), and CD138 (clone 
281-2). All mAbs were purchased from R&D Systems, BioLegend, 
or eBioscience. Flow count beads (BD Biosciences) were added to 
each sample to determine with accuracy the number of the indicated 
cell populations. Samples were acquired on a LSR IV Fortessa Flow 
 1. Palumbo A, Anderson K. Multiple myeloma.  
N Engl J Med. 2011;364(11):1046–1060.
 2. Kuehl WM, Bergsagel PL. Molecular pathogen-
esis of multiple myeloma and its premalignant 
precursor. J Clin Invest. 2012;122(10):3456–3463.
 3. Avet-Loiseau H, et al. Long-term analysis of the 
IFM 99 trials for myeloma: cytogenetic abnor-
malities [t(4;14), del(17p), 1q gains] play a major 
role in defining long-term survival. J Clin Oncol. 
2012;30(16):1949–1952.
 4. Schreiber RD, Old LJ, Smyth MJ. Cancer immu-
noediting: integrating immunity’s roles in 
cancer suppression and promotion. Science. 
2011;331(6024):1565–1570.
 5. Galon J, et al. Type, density, and location 
of immune cells within human colorectal 
tumors predict clinical outcome. Science. 
2006;313(5795):1960–1964.
 6. Dhodapkar MV, et al. A reversible defect in nat-
ural killer T cell function characterizes the pro-
gression of premalignant to malignant multiple 
myeloma. J Exp Med. 2003;197(12):1667–1676.
 7. Dhodapkar MV, Krasovsky J, Olson K. T cells 
from the tumor microenvironment of patients 
with progressive myeloma can generate strong, 
tumor-specific cytolytic responses to autologous, 
tumor-loaded dendritic cells. Proc Natl Acad Sci 
U S A. 2002;99(20):13009–13013.
 8. El-Sherbiny YM, et al. The requirement for 
DNAM-1, NKG2D, and NKp46 in the natural 
killer cell-mediated killing of myeloma cells. 
Cancer Res. 2007;67(18):8444–8449.
 9. Carbone E, et al. HLA class I, NKG2D, and 
natural cytotoxicity receptors regulate multiple 
myeloma cell recognition by natural killer cells. 
Blood. 2005;105(1):251–258.
 10. Osterborg A, Nilsson B, Bjorkholm M, Holm G, 
Mellstedt H. Natural killer cell activity in mono-
clonal gammopathies: relation to disease activity. 
Eur J Haematol. 1990;45(3):153–157.
 11. Jinushi M, et al. MHC class I chain-related protein 
A antibodies and shedding are associated with 
the progression of multiple myeloma. Proc Natl 
Acad Sci U S A. 2008;105(4):1285–1290.
 12. Davies FE, et al. Thalidomide and immuno-
modulatory derivatives augment natural killer 
cell cytotoxicity in multiple myeloma. Blood. 
2001;98(1):210–216.
 13. Kronke J, et al. Lenalidomide causes selective 
degradation of IKZF1 and IKZF3 in multiple mye-
loma cells. Science. 2014;343(6168):301–305.
 14. Quach H, et al. Mechanism of action of immuno-
modulatory drugs (IMiDS) in multiple myeloma. 
Leukemia. 2010;24(1):22–32.
 15. Chan CJ, et al. DNAM-1/CD155 interactions pro-
mote cytokine and NK cell-mediated suppression 
of poorly immunogenic melanoma metastases.  
J Immunol. 2010;184(2):902–911.
 16. Gilfillan S, et al. DNAM-1 promotes activation 
of cytotoxic lymphocytes by nonprofessional 
antigen-presenting cells and tumors. J Exp Med. 
2008;205(13):2965–2973.
 17. Lakshmikanth T, et al. NCRs and DNAM-1 medi-
ate NK cell recognition and lysis of human and 
mouse melanoma cell lines in vitro and in vivo.  
J Clin Invest. 2009;119(5):1251–1263.
 18. Iguchi-Manaka A, et al. Accelerated tumor 
growth in mice deficient in DNAM-1 receptor.  
J Exp Med. 2008;205(13):2959–2964.
 19. Shibuya A, et al. DNAM-1, a novel adhesion 
molecule involved in the cytolytic function of T 
lymphocytes. Immunity. 1996;4(6):573–581.
 20. de Andrade LF, Smyth MJ, Martinet L. DNAM-1 
control of natural killer cells functions through 
nectin and nectin-like proteins. Immunol Cell 
Biol. 2014;92(3):237–244.
 21. Chan CJ, et al. The receptors CD96 and CD226 
oppose each other in the regulation of natural killer 
The Journal of Clinical Investigation   R e s e a R c h  a R t i c l e
2 0 8 9jci.org   Volume 125   Number 5   May 2015
cell functions. Nat Immunol. 2014;15(5):431–438.
 22. Ramsbottom KM, et al. Cutting edge: DNAX acces-
sory molecule 1-deficient CD8+ T cells display 
immunological synapse defects that impair antitu-
mor immunity. J Immunol. 2014;192(2):553–557.
 23. Lozano E, Joller N, Cao Y, Kuchroo VK, Hafler 
DA. The CD226/CD155 interaction regulates 
the proinflammatory (Th1/Th17)/anti-inflam-
matory (Th2) balance in humans. J Immunol. 
2013;191(7):3673–3680.
 24. Shibuya K, et al. CD226 (DNAM-1) is involved 
in lymphocyte function-associated antigen 
1 costimulatory signal for naive T cell dif-
ferentiation and proliferation. J Exp Med. 
2003;198(12):1829–1839.
 25. Gasser S, Orsulic S, Brown EJ, Raulet DH. The 
DNA damage pathway regulates innate immune 
system ligands of the NKG2D receptor. Nature. 
2005;436(7054):1186–1190.
 26. Soriani A, et al. ATM-ATR-dependent up-reg-
ulation of DNAM-1 and NKG2D ligands on 
multiple myeloma cells by therapeutic agents 
results in enhanced NK-cell susceptibility and is 
associated with a senescent phenotype. Blood. 
2009;113(15):3503–3511.
 27. Anderson KC, Carrasco RD. Pathogenesis of 
myeloma. Annu Rev Pathol. 2011;6:249–274.
 28. Chesi M, et al. AID-dependent activation of a 
MYC transgene induces multiple myeloma in a 
conditional mouse model of post-germinal center 
malignancies. Cancer Cell. 2008;13(2):167–180.
 29. Keats JJ, et al. Clonal competition with alter-
nating dominance in multiple myeloma. Blood. 
2012;120(5):1067–1076.
 30. Chesi M, et al. Drug response in a genetically 
engineered mouse model of multiple mye-
loma is predictive of clinical efficacy. Blood. 
2012;120(2):376–385.
 31. Matthews GM, et al. Preclinical screening of 
histone deacetylase inhibitors combined with 
ABT-737, rhTRAIL/MD5-1 or 5-azacytidine 
using syngeneic Vk*MYC multiple myeloma. Cell 
Death Dis. 2013;4:e798.
 32. Smyth MJ, Thia KY, Street SE, MacGregor D, 
Godfrey DI, Trapani JA. Perforin-mediated cyto-
toxicity is critical for surveillance of spontaneous 
lymphoma. J Exp Med. 2000;192(5):755–760.
 33. Street SE, Cretney E, Smyth MJ. Perforin and 
interferon-gamma activities independently 
control tumor initiation, growth, and metastasis. 
Blood. 2001;97(1):192–197.
 34. Obeid M, et al. Calreticulin exposure dictates the 
immunogenicity of cancer cell death. Nat Med. 
2007;13(1):54–61.
 35. Kroemer G, Galluzzi L, Kepp O, Zitvogel L. 
Immunogenic cell death in cancer therapy. Annu 
Rev Immunol. 2012;31:51–72.
 36. Flemming A. Cancer: PD1 makes waves in anti-
cancer immunotherapy. Nat Rev Drug Discov. 
2012;11(8):601.
 37. Hamid O, et al. Safety and tumor responses with 
lambrolizumab (anti-PD-1) in melanoma. N Engl 
J Med. 2013;369(2):134–144.
 38. Kaplan MG. Ipilimumab plus dacarbazine in mel-
anoma. N Engl J Med. 2011;365(13):1256–1257.
 39. Ngiow SF, Knight DA, Ribas A, McArthur GA, Smyth 
MJ. BRAF-targeted therapy and immune responses 
to melanoma. Oncoimmunology. 2013;2(6):e24462.
 40. Simpson TR, et al. Fc-dependent depletion of 
tumor-infiltrating regulatory T cells co-defines 
the efficacy of anti-CTLA-4 therapy against mel-
anoma. J Exp Med. 2013;210(9):1695–1710.
 41. Neben K, et al. Progression in smoldering mye-
loma is independently determined by the chro-
mosomal abnormalities del(17p), t(4;14), gain 
1q, hyperdiploidy, and tumor load. J Clin Oncol. 
2013;31(34):4325–4332.
 42. Affer M, et al. Promiscuous MYC locus rearrange-
ments hijack enhancers but mostly super- 
enhancers to dysregulate MYC expression in mul-
tiple myeloma. Leukemia. 2014;28(8):1725–1735.
 43. Lowe SW, Cepero E, Evan G. Intrinsic tumour 
suppression. Nature. 2004;432(7015):307–315.
 44. Unni AM, Bondar T, Medzhitov R. Intrinsic sen-
sor of oncogenic transformation induces a signal 
for innate immunosurveillance. Proc Natl Acad 
Sci U S A. 2008;105(5):1686–1691.
 45. Liu XV, Ho SS, Tan JJ, Kamran N, Gasser S. 
Ras activation induces expression of Raet1 
family NK receptor ligands. J Immunol. 
2012;189(4):1826–1834.
 46. Chan CJ, Smyth MJ, Martinet L. Molecular mecha-
nisms of natural killer cell activation in response to 
cellular stress. Cell Death Differ. 2014;21(1):5–14.
 47. Croxford JL, et al. ATM-dependent spontaneous 
regression of early Emu-myc-induced murine B 
cell leukemia depends on NK and T cells. Blood. 
2013;121(13):2512–2521.
 48. Bottino C, et al. Identification of PVR (CD155) 
and Nectin-2 (CD112) as cell surface ligands for 
the human DNAM-1 (CD226) activating mole-
cule. J Exp Med. 2003;198(4):557–567.
 49. Tahara-Hanaoka S, et al. Functional characteriza-
tion of DNAM-1 (CD226) interaction with its lig-
ands PVR (CD155) and nectin-2 (PRR-2/CD112). 
Int Immunol. 2004;16(4):533–538.
 50. Stanietsky N, et al. Mouse TIGIT inhibits NK-cell 
cytotoxicity upon interaction with PVR. Eur J 
Immunol. 2013;43(8):2138–2150.
 51. Ghiringhelli F, et al. CD4+CD25+ regulatory T 
cells suppress tumor immunity but are sensitive 
to cyclophosphamide which allows immunother-
apy of established tumors to be curative. Eur J 
Immunol. 2004;34(2):336–344.
 52. Ghiringhelli F, et al. Metronomic cyclophos-
phamide regimen selectively depletes CD4+CD25+ 
regulatory T cells and restores T and NK effector 
functions in end stage cancer patients. Cancer 
Immunol Immunother. 2007;56(5):641–648.
 53. Lutsiak ME, Semnani RT, De Pascalis R, Kash-
miri SV, Schlom J, Sabzevari H. Inhibition of 
CD4(+)25+ T regulatory cell function implicated 
in enhanced immune response by low-dose cyclo-
phosphamide. Blood. 2005;105(7):2862–2868.
 54. Smyth MJ, Teng MW, Swann J, Kyparissoudis 
K, Godfrey DI, Hayakawa Y. CD4+CD25+ 
T regulatory cells suppress NK cell-medi-
ated immunotherapy of cancer. J Immunol. 
2006;176(3):1582–1587.
 55. Lundqvist A, Berg M, Smith A, Childs RW.  
Bortezomib treatment to potentiate the anti- 
tumor immunity of ex-vivo expanded adoptively 
infused autologous Natural Killer cells. J Cancer. 
2011;2:383–385.
 56. Lundqvist A, Yokoyama H, Smith A, Berg M, 
Childs R. Bortezomib treatment and regula-
tory T-cell depletion enhance the antitumor 
effects of adoptively infused NK cells. Blood. 
2009;113(24):6120–6127.
 57. Shi J, et al. Bortezomib down-regulates the cell-
surface expression of HLA class I and enhances 
natural killer cell-mediated lysis of myeloma. 
Blood. 2008;111(3):1309–1317.
 58. Spisek R, Charalambous A, Mazumder A, Vesole 
DH, Jagannath S, Dhodapkar MV. Bortezomib 
enhances dendritic cell (DC)-mediated induction 
of immunity to human myeloma via exposure 
of cell surface heat shock protein 90 on dying 
tumor cells: therapeutic implications. Blood. 
2007;109(11):4839–4845.
 59. Couzin-Frankel J. Breakthrough of the year 
2013. Cancer immunotherapy. Science. 
2013;342(6165):1432–1433.
 60. Topalian SL, et al. Safety, activity, and immune 
correlates of anti-PD-1 antibody in cancer. N Engl 
J Med. 2012;366(26):2443–2454.
 61. Atanackovic D, Luetkens T, Kroger N. Coinhib-
itory molecule PD-1 as a potential target for the 
immunotherapy of multiple myeloma. Leukemia. 
2014;28(5):993–1000.
 62. Hallett WH, Jing W, Drobyski WR, Johnson BD. 
Immunosuppressive effects of multiple myeloma 
are overcome by PD-L1 blockade. Biol Blood Mar-
row Transplant. 2011;17(8):1133–1145.
 63. Benson DM, et al. The PD-1/PD-L1 axis mod-
ulates the natural killer cell versus multiple 
myeloma effect: a therapeutic target for CT-011, 
a novel monoclonal anti-PD-1 antibody. Blood. 
2010;116(13):2286–2294.
 64. Rosenblatt J, et al. PD-1 blockade by CT-011, anti-
PD-1 antibody, enhances ex vivo T-cell responses 
to autologous dendritic cell/myeloma fusion 
vaccine. J Immunother. 2011;34(5):409–418.
 65. Melero I, et al. Monoclonal antibodies against the 
4-1BB T-cell activation molecule eradicate estab-
lished tumors. Nat Med. 1997;3(6):682–685.
 66. Lynch DH. The promise of 4-1BB (CD137)-medi-
ated immunomodulation and the immunother-
apy of cancer. Immunol Rev. 2008;222:277–286.
 67. Knight DA, et al. Host immunity contributes to 
the anti-melanoma activity of BRAF inhibitors.  
J Clin Invest. 2013;123(3):1371–1381.
 68. Uno T, et al. Eradication of established tumors in 
mice by a combination antibody-based therapy. 
Nat Med. 2006;12(6):693–698.
 69. Verbrugge I, et al. Radiotherapy increases the 
permissiveness of established mammary tumors 
to rejection by immunomodulatory antibodies. 
Cancer Res. 2012;72(13):3163–3174.
 70. Li SY, Liu Y. Immunotherapy of melanoma 
with the immune costimulatory monoclonal 
antibodies targeting CD137. Clin Pharmacol. 
2013;5(suppl 1):47–53.
 71. Johnston RJ, et al. The immunoreceptor TIGIT reg-
ulates antitumor and antiviral CD8(+) T cell effec-
tor function. Cancer Cell. 2014;26(6):923–937.
 72. Murillo O, et al. Therapeutic antitumor efficacy 
of anti-CD137 agonistic monoclonal antibody 
in mouse models of myeloma. Clin Cancer Res. 
2008;14(21):6895–6906.
 73. von Scheidt B, et al. Combined anti-CD40 and 
anti-IL-23 monoclonal antibody therapy effec-
tively suppresses tumor growth and metastases. 
Cancer Res. 2014;74(9):2412–2421.
